Key Takeaways & Executive Findings
- •• CTNNAL1 is essential for maintaining airway epithelial structural integrity under ozone stress, as its knockdown leads to epithelial denudation and damage in mice. • Silencing CTNNAL1 in human bronchial epithelial cells reduces proliferation and weakens cell-matrix and cell-cell adhesion, likely via cytoskeletal disruption. • CTNNAL1 regulates the expression of adhesion molecules (E-cadherin, integrin β1, integrin β4) through the RhoA/ROCK1 signaling pathway. • The ROCK inhibitor Y27632 reverses ozone-induced adhesion molecule expression in CTNNAL1-overexpressing cells, highlighting a potential therapeutic target for airway diseases.
Abstract
Adhesion molecules play critical roles in maintaining the structural integrity of the airway epithelium in airways under stress. Previously, we reported that catenin alpha-like 1 (CTNNAL1) is downregulated in an asthma animal model and upregulated at the edge of human bronchial epithelial cells (HBECs) after ozone stress. In this work, we explore the potential role of CTNNAL1 in the structural adhesion of HBECs and its possible mechanism. We construct a CTNNAL1‒/‒ mouse model with CTNNAL1-RNAi recombinant adeno-associated virus (AAV) in the lung and a CTNNAL1-silencing cell line stably transfected with CTNNAL1-siRNA recombinant plasmids. Hematoxylin and eosin (HE) staining reveals that CTNNAL1‒/‒ mice have denuded epithelial cells and structural damage to the airway. Silencing of CTNNAL1 in HBECs inhibits cell proliferation and weakens extracellular matrix adhesion and intercellular adhesion, possibly through the action of the cytoskeleton. We also find that the expressions of the structural adhesion-related molecules E-cadherin, integrin β1, and integrin β4 are significantly decreased in ozone-treated cells than in vector control cells. In addition, our results show that the expression levels of RhoA/ROCK1 are decreased after CTNNAL1 silencing. Treatment with Y27632, a ROCK inhibitor, abolished the expressions of adhesion molecules induced by ozone in CTNNAL1-overexpressing HBECs. Overall, the findings of the present study suggest that CTNNAL1 plays a critical role in maintaining the structural integrity of the airway epithelium under ozone challenge, and is associated with epithelial cytoskeleton dynamics and the expressions of adhesion-related molecules via the RhoA/ROCK1 pathway.
1. Introduction
Adhesion molecules on the airway epithelium are a large family of transmembrane receptors that have been identified to be important for maintaining epithelial integrity, maintaining homeostasis, and promoting the inflammatory response [1–3]. Destruction of bronchial epithelial integrity induced by abnormal adhesion is critical for asthma pathogenesis [4,5]. In our previous study, we found that the expression of catenin alpha-like 1 (CTNNAL1) is downregulated in asthma patients and in an ovalbumin-stressed asthmatic mouse model, but markedly increased in human bronchial epithelial cells (HBECs) in the lungs and at the edge of HBECs exposed to ozone stress [6–8]. Moreover, CTNNAL1 has been shown to promote wound repair in bronchial epithelial cells (BECs), inhibit ozone-induced airway epithelial-mesenchymal transition, and regulate mucus hypersecretion induced by house dust mite (HDM) [9,10]. These data indicate that CTNNAL1 may have a protective effect on airway epithelial homeostasis.
The maintenance of respiratory microenvironment homeostasis depends on the airway epithelium. In the presence of environmental pollutants and allergens, the airway epithelium not only acts as an initial barrier but also participates in inflammatory activation. An increasing number of studies have shown that airway epithelial cells play a central role in the pathogenesis of airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD) [11,12]. The denudation of ciliated cells in asthma patients suggests that the airway epithelial barrier is often compromised [12,13]. Therefore, we hypothesized that CTNNAL1 may be involved in the structural integrity of airway epithelial cells.
Loading authentic research manuscript (Pages 1–5)...
Caixia Liu, Jinmei Wang, Yurong Tan, Chi Liu, Xiangping Qu, Huijun Liu, Meiling Tan, Changqing Deng, Xiaoqun Qin, Yang Xiang (2026). CTNNAL1 promotes the structural integrity of bronchial epithelial cells through the RhoA/ROCK1 pathway. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024026
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of CTNNAL1 in bronchial epithelial cells?
CTNNAL1 is critical for maintaining the structural integrity of bronchial epithelial cells, particularly under ozone stress. It promotes cell adhesion and proliferation, and regulates the expression of adhesion molecules via the RhoA/ROCK1 pathway.
How does CTNNAL1 affect airway epithelial integrity?
CTNNAL1 supports airway epithelial integrity by enhancing cell-matrix and cell-cell adhesion, and by regulating cytoskeletal dynamics. Its deficiency leads to epithelial denudation and structural damage in the airway.
What is the significance of the RhoA/ROCK1 pathway in this study?
The RhoA/ROCK1 pathway is a downstream mediator of CTNNAL1's effects on adhesion molecule expression. Inhibition of ROCK1 with Y27632 abolished ozone-induced adhesion molecule expression in CTNNAL1-overexpressing cells, indicating that this pathway is essential for CTNNAL1's protective function.
What are the potential therapeutic implications of this research?
Targeting CTNNAL1 or the RhoA/ROCK1 pathway may offer new strategies for treating airway diseases like asthma, where epithelial barrier dysfunction is a key feature. Enhancing CTNNAL1 expression or modulating ROCK1 activity could help restore epithelial integrity.
How was the CTNNAL1 knockout model generated?
The CTNNAL1 knockout mouse model was generated using CTNNAL1-RNAi recombinant adeno-associated virus (AAV) delivered to the lung, resulting in reduced CTNNAL1 expression and subsequent airway epithelial damage.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.